| Adams County Memorial Hospital | |
|
1100 Mercer Ave Decatur IN 46733-2303 | |
| (260) 724-2145 | |
| (260) 728-3867 |
| Full Name | Adams County Memorial Hospital |
|---|---|
| Speciality | General Acute Care Hospital |
| Location | 1100 Mercer Ave, Decatur, Indiana |
| Authorized Official Name and Position | Dane Wheeler (CFO) |
| Authorized Official Contact | 2607242145 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Adams County Memorial Hospital 1100 Mercer Avenue P.o. Box 151 Decatur IN 46733 Ph: (260) 724-2145 | Adams County Memorial Hospital 1100 Mercer Ave Decatur IN 46733-2303 Ph: (260) 724-2145 |
| NPI Number | 1689696148 |
|---|---|
| Provider Enumeration Date | 07/24/2006 |
| Last Update Date | 10/11/2017 |
| Medicare PECOS PAC ID | 0941198253 |
|---|---|
| Medicare Enrollment ID | O20041001000326 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689696148 | NPI | - | NPPES |
| 100268270A | Medicaid | IN | |
| 000000097902 | Other | IN | BLUE CROSS |
| 100146660A | Medicaid | IN |
| Provider Name | David W Shepherd |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1942266911 PECOS PAC ID: 8921992652 Enrollment ID: I20040212000168 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Richard J Iarussi |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1679571855 PECOS PAC ID: 2365335429 Enrollment ID: I20040814000089 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Steven Schneider |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1871559385 PECOS PAC ID: 0446225635 Enrollment ID: I20041110000789 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Anthony C Cheng |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1548267875 PECOS PAC ID: 0244284487 Enrollment ID: I20050310000060 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | David S Colclasure |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1699740191 PECOS PAC ID: 1254372485 Enrollment ID: I20050518000814 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Keith Harvey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295718062 PECOS PAC ID: 7012828874 Enrollment ID: I20050629000767 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Scott L Tarlton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1417974288 PECOS PAC ID: 0840220067 Enrollment ID: I20050817000831 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | John David Wagel |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1487630414 PECOS PAC ID: 5698705663 Enrollment ID: I20050818000982 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Brenda Kaye Dearmond |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568433746 PECOS PAC ID: 1658399126 Enrollment ID: I20051103000769 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Cameron V Nelson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700866183 PECOS PAC ID: 7810958014 Enrollment ID: I20070426000036 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Thomandram S Sekar |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1295838464 PECOS PAC ID: 3678667615 Enrollment ID: I20070921000070 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Nicholas L Nussbaum |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720107824 PECOS PAC ID: 9830262070 Enrollment ID: I20080721000535 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Mark R Ranzinger |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1457339111 PECOS PAC ID: 7911960380 Enrollment ID: I20080815000127 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Matthew R Sutter |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1548287501 PECOS PAC ID: 9931297827 Enrollment ID: I20080825000565 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Amy M Weaver |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619967031 PECOS PAC ID: 8224195292 Enrollment ID: I20090318000236 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Craig E Hanson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1578600565 PECOS PAC ID: 6608886874 Enrollment ID: I20090331000572 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Yu Liu |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1043415706 PECOS PAC ID: 5395846901 Enrollment ID: I20090413000037 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Denise Murphy |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1104810431 PECOS PAC ID: 9234287392 Enrollment ID: I20090429000017 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | David A Coats |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1679612006 PECOS PAC ID: 6709931777 Enrollment ID: I20090827000596 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Jessamine Ashle Hippensteel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457528820 PECOS PAC ID: 1850446741 Enrollment ID: I20090828000072 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Debra K Brandenberger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063412419 PECOS PAC ID: 4587704739 Enrollment ID: I20091218000172 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Michael E Ainsworth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629058698 PECOS PAC ID: 2668513516 Enrollment ID: I20100114000152 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Tamara J Reynolds |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336237320 PECOS PAC ID: 2365576105 Enrollment ID: I20100817000096 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Amanda M Selking |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902125727 PECOS PAC ID: 3375677750 Enrollment ID: I20100820000540 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Alisha K Brincefield |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841511979 PECOS PAC ID: 4385760883 Enrollment ID: I20100921001406 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Keith R Schreffler |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1013993351 PECOS PAC ID: 2466352026 Enrollment ID: I20101008000825 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Nicholas Lazoff |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891830345 PECOS PAC ID: 3476746058 Enrollment ID: I20101015000706 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Scott T Smith |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1427183169 PECOS PAC ID: 8123211505 Enrollment ID: I20101018000908 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Mark S Gresla |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467482034 PECOS PAC ID: 7214826247 Enrollment ID: I20101221000635 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Michael Ryskin |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1326007774 PECOS PAC ID: 0446285571 Enrollment ID: I20110906000703 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Adam D Will |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1932363587 PECOS PAC ID: 5294999744 Enrollment ID: I20120613000065 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Kathleen A Heimann |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1962630426 PECOS PAC ID: 3173774411 Enrollment ID: I20121113000566 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Ann Geimer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558596478 PECOS PAC ID: 7618102757 Enrollment ID: I20131028001043 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Syed Mustafa Hasan |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1891080883 PECOS PAC ID: 0042460644 Enrollment ID: I20140418000076 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Neal Agee |
|---|---|
| Provider Type | Practitioner - Surgical Oncology |
| Provider Identifiers | NPI Number: 1295005395 PECOS PAC ID: 9638399207 Enrollment ID: I20141002000161 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Shauna L Glenn |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1285934273 PECOS PAC ID: 1254512981 Enrollment ID: I20150507001710 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Robert A Green |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1952745499 PECOS PAC ID: 1456593680 Enrollment ID: I20150730012940 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Brittany Rumple |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831574656 PECOS PAC ID: 3173832946 Enrollment ID: I20151016001637 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Mary E Cole |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518377522 PECOS PAC ID: 2961626213 Enrollment ID: I20151019001847 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Tawny E Avila |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1932461696 PECOS PAC ID: 1951529635 Enrollment ID: I20160321001324 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Leah D Keller |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1992091797 PECOS PAC ID: 6507154374 Enrollment ID: I20161011001002 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Tommy Wayne Lyons |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1548257652 PECOS PAC ID: 2163494006 Enrollment ID: I20161209002042 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | David B Murphy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750762506 PECOS PAC ID: 9335451541 Enrollment ID: I20161213002013 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Jennifer E Taylor |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1093079923 PECOS PAC ID: 0648580878 Enrollment ID: I20170628001314 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Timm M Reed |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508394693 PECOS PAC ID: 1052680618 Enrollment ID: I20170713001197 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Baldemar Silva |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114430378 PECOS PAC ID: 1557629037 Enrollment ID: I20171212000841 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Joshua J Fullenkamp |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730680372 PECOS PAC ID: 6709148166 Enrollment ID: I20180322001714 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Amber Lautzenheiser |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1881089787 PECOS PAC ID: 6305151762 Enrollment ID: I20180720001273 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Monalisa A Rodgers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003315466 PECOS PAC ID: 1850648809 Enrollment ID: I20180720002727 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | John C. Huddlestone |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1770692865 PECOS PAC ID: 4789923707 Enrollment ID: I20190308000239 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Meghan Arndts |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1487863171 PECOS PAC ID: 3173821279 Enrollment ID: I20190314001538 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Mary Jacqueline Wharton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992265904 PECOS PAC ID: 8224370465 Enrollment ID: I20190508002091 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Beth Kaskel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477119386 PECOS PAC ID: 9638402340 Enrollment ID: I20190612002318 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Robert James Kinne |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1265870588 PECOS PAC ID: 1355645391 Enrollment ID: I20190625003221 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Elizabeth Hollingsworth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437508124 PECOS PAC ID: 3971894783 Enrollment ID: I20190905000853 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Sarah Cearns |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1386287183 PECOS PAC ID: 6002241411 Enrollment ID: I20200219002465 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Leyuan Chen |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1053766303 PECOS PAC ID: 5193019073 Enrollment ID: I20200417002200 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Deyanira Chen |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1922494228 PECOS PAC ID: 7315239183 Enrollment ID: I20200424000940 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Tracey Ann Pruden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699390179 PECOS PAC ID: 0840619201 Enrollment ID: I20201005000101 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Maybelle Holt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780276485 PECOS PAC ID: 9436564275 Enrollment ID: I20210209001343 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Kayla Schaab |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730857798 PECOS PAC ID: 2466859285 Enrollment ID: I20210921003874 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | William Whitacre |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1588635635 PECOS PAC ID: 0143312512 Enrollment ID: I20211007001222 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Samantha Rose Vergara |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033887021 PECOS PAC ID: 0244621159 Enrollment ID: I20220104001933 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Alec Arturi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1063901551 PECOS PAC ID: 0648690552 Enrollment ID: I20220215000864 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Aimie D Greulach |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366013021 PECOS PAC ID: 5496140501 Enrollment ID: I20220328000086 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Haleigh Jordan Nidlinger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356011266 PECOS PAC ID: 6709263882 Enrollment ID: I20220510002610 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Elizabeth Ann Blume |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033856992 PECOS PAC ID: 4284014598 Enrollment ID: I20220705001202 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Annette Elizabeth Edgell |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1750933412 PECOS PAC ID: 9830570563 Enrollment ID: I20220713000445 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Stephanie Lothamer |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1619527686 PECOS PAC ID: 3577946300 Enrollment ID: I20220811002002 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Dylan Reagan |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1962141648 PECOS PAC ID: 9638552680 Enrollment ID: I20220824000719 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Kaylin Lutter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033849088 PECOS PAC ID: 8729456017 Enrollment ID: I20221117000473 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Chelsi Line |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1427783018 PECOS PAC ID: 2769854496 Enrollment ID: I20230207000578 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Alyssa Hoopingarner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992403505 PECOS PAC ID: 8921463423 Enrollment ID: I20230506000277 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Tobin Lee Eicher |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1760011704 PECOS PAC ID: 9133506454 Enrollment ID: I20230823004440 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Cameron Jeffrey Lautzenheiser |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316621659 PECOS PAC ID: 5890158869 Enrollment ID: I20230824001761 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Modnath Sangroula |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1952900250 PECOS PAC ID: 5698138501 Enrollment ID: I20230824004165 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Bettie Ann Shawler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588986665 PECOS PAC ID: 0345603148 Enrollment ID: I20230828000310 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Benjamin Hart |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1093210072 PECOS PAC ID: 4183970833 Enrollment ID: I20230912000520 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Lisa Ferrando |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366071128 PECOS PAC ID: 0345661286 Enrollment ID: I20230913004136 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Paige Reinhart |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1114332822 PECOS PAC ID: 0244644284 Enrollment ID: I20231122001844 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Carrie Ann Binegar |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1730466236 PECOS PAC ID: 7416306154 Enrollment ID: I20231207000508 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Dominique Sanchez |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972036093 PECOS PAC ID: 8123397205 Enrollment ID: I20240117001512 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
| Provider Name | Maria M Snyder |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215551007 PECOS PAC ID: 2163845686 Enrollment ID: I20240305004125 |
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
News Archive
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it received a contract from the U.S. Army to develop an investigational device based on the success of the Signal-X6 telemedicine systems recently deployed to the Army under a separate contract.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Drew, a 65-year-old man from Connecticut, was living an adventurous life until he started to experience unusual muscle weakness in his legs and unexplained fatigued. What he thought was possibly Lyme disease, or symptoms of normal aging, turned out to be much more serious.
The Federation of State Medical Boards (FSMB) has been awarded a three-year grant from the U.S. Health Resources and Services Administration (HRSA) to continue initiatives currently underway to streamline the state medical licensure process and reduce statutory and regulatory barriers to telemedicine. The grant is the third the FSMB has received from HRSA since 2006 to facilitate license portability.
› Verified 9 days ago
Keith A. Harvey Md; Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 955 High St, Ste 1, Decatur, IN 46733 Phone: 260-724-2145 Fax: 260-728-3858 | |
Decatur Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1100 Mercer Ave, Decatur, IN 46733 Phone: 260-728-3843 Fax: 260-728-3848 | |
Adams County Memorial Hospital Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 955 High St, Decatur, IN 46733 Phone: 260-724-2145 Fax: 260-728-3852 | |
Acfp Decatur Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 955 High St, Suite 3, Decatur, IN 46733 Phone: 260-724-2125 Fax: 260-724-3859 | |
Hometown Healthcare Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 955 High St, Ste 2, Decatur, IN 46733 Phone: 260-724-8700 Fax: 260-728-3821 | |
Decatur Family Medicine - Woodcrest Connection Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1300 Mercer Ave, Decatur, IN 46733 Phone: 260-724-2145 |